S-Evans Biosciences Obtains China Rights for Stem Cell Technology From Cryo-Cell International

ChinaBio Today -- S-Evans Biosciences (SEB) of Hangzhou has received an exclusive license to market and manufacture the C’elle menstrual stem cell technology developed by Cryo-Cell. The rights, which are good throughout mainland China, include processing and storage of menstrual stem cells. The deal also allows SEB to conduct research using this platform to identify potential therapeutic applications for a range of diseases.

MORE ON THIS TOPIC